Ido Nofech-Mozes

Ido Nofech-Mozes

Auto-generated profile, based on publicly available information

Ido Nofech-Mozes

Ontario Institute for Cancer Research, Toronto, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
INIdo Nofech-Mozes
Ido Nofech-Mozes
DSDavid Soave
David Soave
PAPhilip Awadalla
Philip Awadalla
SASagi Abelson
Sagi Abelson
Single-cell RNA sequencing can reveal valuable insights into cellular heterogeneity within tumour microenvironments (TMEs), paving the way for a deep understanding of cellular mechanisms contributing to cancer. However, high heterogeneity among the same cancer types and low transcriptomic variation in immune cell subsets present challenges for accurate, high-resolution confirmation of cells’ identities. Here we present scATOMIC; a modular annotation tool for malignant and non-malignant cells. We trained scATOMIC on >300,000 cancer, immune, and stromal cells defining a pan-cancer reference across 19 common cancers and employ a hierarchical approach, outperforming current classification methods. We extensively confirm scATOMIC’s accuracy on 225 tumour biopsies encompassing >350,000 cancer and a variety of TME cells. Lastly, we demonstrate scATOMIC’s practical significance to accurately subset breast cancers into clinically relevant subtypes and predict tumours’ primary origin across metastatic cancers. Our approach represents a broadly applicable strategy to analyse multicellular cancer TMEs.

11 December 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
SASagi Abelson
Sagi Abelson
AZAndy G. X. Zeng
Andy G. X. Zeng
INIdo Nofech-Mozes
Ido Nofech-Mozes
TWTing Ting Wang
Ting Ting Wang
SNStanley W. K. Ng
Stanley W. K. Ng
SBScott Bratman
Scott Bratman
Espresso efficiently distinguishes true mutations from background noise common in deep sequencing data.

14 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSalman Basrai
Salman Basrai
INIdo Nofech-Mozes
Ido Nofech-Mozes
RDRajesh Detroja
Rajesh Detroja
FSFernando L. Scolari
Fernando L. Scolari
MBMehran Bakhtiari
Mehran Bakhtiari
SASagi Abelson
Sagi Abelson
The abundance, dynamics, and context-dependent heterogeneity of DNA methylation, where a pattern considered abnormal in one cell type may be normal in another, complicate the identification of early methylation changes that drive or signal disease development. This complexity can obscure early markers of increased disease risk, making it challenging to detect and intervene in disease processes at their inception. Here, we report 31,744 CpG loci exhibiting highly consistent methylation profiles in the blood of young, healthy individuals. We assess alterations at these epigenetically stable loci in 8,886 individuals across 29 diverse cohorts, including those with hematological cancers (n = 3159), cardiovascular complications (n = 2788), and healthy controls (n = 2939). Our findings reveal methylation pattern disruption in myeloid and lymphoid malignancies, correlating with clonal burden dynamics and mutation frequency throughout leukemia treatment. In non-cancer cohorts, we observe that methylation levels at epigenetically stable loci become increasingly variable with age, a shift linked to higher cardiovascular disease risk and lower survival rates. This study highlights DNA methylation instability as a blood-based biomarker for both hematological cancer and cardiovascular disease and uncovers a mechanistic link between methylation dynamics and the expansion of maladaptive hematopoietic clones.

16 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
INIdo Nofech-Mozes
Ido Nofech-Mozes
DSDavid Soave
David Soave
PAPhilip Awadalla
Philip Awadalla
SASagi Abelson
Sagi Abelson
Single-cell RNA sequencing reveals valuable insights into cellular heterogeneity within tumour microenvironments (TMEs), paving the way for a deep understanding of cellular mechanisms contributing to cancer. However, high heterogeneity among the same cancer types and low transcriptomic variation in immune cell subsets present challenges for accurate, high-resolution confirmation of cells’ identities. Here we present scATOMIC; a modular annotation tool for malignant and non-malignant cells. We trained scATOMIC on >250,000 cancer, immune, and stromal cells defining a pan-cancer reference across 19 common cancer types and employed a novel hierarchical approach, outperforming current classification methods. We extensively confirmed scATOMIC’s accuracy on 198 tumour biopsies and 54 blood samples encompassing >420,000 cancer and a variety of TME cells. Lastly, we demonstrate scATOMIC’s practical significance to accurately subset breast cancers into clinically relevant subtypes and predict tumours’ primary origin across metastatic cancers. Our approach represents a broadly applicable strategy to analyze multicellular cancer TMEs.

7 January 2026 in bioRxiv
Verified
Preprint
Open access
INIdo Nofech-Mozes
Ido Nofech-Mozes
ACAshton Cook
Ashton Cook
TOTom W Ouellette
Tom W Ouellette
SHSara Hafezi-Bakhtiari
Sara Hafezi-Bakhtiari
PAPhilip Awadalla
Philip Awadalla
SASagi Abelson
Sagi Abelson
Intratumoural heterogeneity remains one of the most formidable challenges in oncology, driving treatment resistance, disease progression, and poor patient outcomes. To uncover the cellular programs that define tumour composition and diversity, we interrogated over 3.6 million single cells derived from more than 1,000 primary and metastatic tumours spanning 14 diverse cancer types. Through the identification and quantification of coordinated gene expression programs, we delineated heterogeneous cancer cell states, exhibiting unique and clinically significant associations with patient survival. Integration with high-resolution spatial transcriptomics identified prognostic cancer cell states marked by aggressive transcriptional programs, co-localizing with invasive histological features and significantly enriched in metastatic settings. Functional drug perturbation screening uncovered drug vulnerabilities specific to distinct cancer cell states, supporting both direct targeting strategies and therapeutic reprogramming toward less aggressive cellular phenotypes. Collectively, this study offers novel insights into the relationship between intratumoural transcriptional heterogeneity, spatial organization, clinical outcomes, and therapeutic vulnerabilities.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
INIdo Nofech-Mozes
Ido Nofech-Mozes
PAPhilip Awadalla
Philip Awadalla
SASagi Abelson
Sagi Abelson
Single-cell RNA sequencing (scRNA-seq) allows for the study of the transcriptome at a cellular level, where populations of cells are annotated based on the expression of marker genes, providing a tool to gain cell-specific, subtle insights on cancer biology. However, precise annotation of cell type remains a challenge, hindering the efficiency of data interpretation. Several existing tools for cell-type annotation have been developed to improve resolution and reproducibility, yet their performance is reduced when the reference dataset contains many cell types, subclasses of similar cell types, or malignant cells. Interpatient malignant cell heterogeneity often leads to reduced accuracy when classifying cancer cells as most methods rely on correlations to a reference from a different source. Given the challenges in the annotation of scRNA-seq data of cancer and its high impact for elucidating mechanisms associated with tumor heterogeneity, pathogenesis, and treatment, we developed a comprehensive, hierarchically organized, multi-layered classifier spanning diverse malignant and normal cells of the tumor microenvironment. We found that performance improves when each layer focuses on a smaller number of classes and each cell sequentially moves down a series of classifiers with increased cell type resolution. When applied to an external validation dataset of over 300 primary solid tumor biopsies spanning diverse cancer types, the classifier accurately annotated the tissue of origin of malignant cells, and relevant subtypes of stromal and blood cells, with average F1 scores of 0.91, 0.95 and 0.99 respectively. Using confidence thresholds at each layer, the classifier abstains from classifying ambiguous cells. We applied 4 existing annotators provided with the same reference to the external test dataset and found that cancer cells are misclassified or unclassified, while the blood and stromal cells are accurately classified, highlighting our tool’s unique ability to classify cancer cells. Moreover, we applied our classifier’s to scRNA-seq data derived from breast cancer metastasis to the liver and were able to uncover the tissue of origin, demonstrating the potential use for determining the source of a metastatic tumour. Finally, given that our classifier is modular, we leveraged two recently published single cell breast cancer atlases to add a breast cancer subtype classification layer, that consistently identified the correct clinical subtype of single breast cancer cells in external data. This study provides a flexible model for the annotation of cells comprising the tumor microenvironment in pan cancer settings, while existing methods require tissue-specific references for every cancer type. Our classifier provides a powerful method for investigating intercellular communication pathways between tumor cells and non-malignant cells of the tumor microenvironment. Citation Format: Ido Nofech-Mozes, Philip Awadalla, Sagi Abelson. Comprehensive cell-type classification of tumor and normal cells from single cell RNA sequencing in pan cancer settings [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1221.